Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5233425 | 0.92 | ESR1 (0.32) | ESR1PTGS1PDE4A | |
| SCHEMBL5235538 | 0.92 | ESR1 (0.37) | ESR1PTGS1PDE4AABCC2 | |
| SCHEMBL13764793 | 0.91 | CCNA2 (0.30) | CCNA2CDK2 | |
| SCHEMBL5232723 | 0.90 | ESR1 (0.33) | ESR1PTGS1PDE4AABCC2 | |
| SCHEMBL5231629 | 0.90 | ESR1 (0.32) | ESR1PTGS1PDE4A | |
| SCHEMBL5232640 | 0.90 | ESR1 (0.34) | ESR1PTGS1PDE4AABCC2 | |
| SCHEMBL13764785 | 0.88 | — | — | |
| SCHEMBL5237067 | 0.88 | ESR1 (0.33) | ESR1PTGS1PDE4AABCC2 | |
| SCHEMBL5230193 | 0.86 | ESR1 (0.33) | ESR1PTGS1PDE4A | |
| SCHEMBL13764757 | 0.85 | CCNA2 (0.31) | CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563901-B2 | Intermediates of 2-substituted carbapenem derivatives and process for production thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-7524951-B2 | Intermediates of 2-substituted carbapenem derivatives and process for production thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20080167475-A1 | Intermediates of 2-substituted carbapenem derivatives and process for production thereof | SASAKI TOSHIRO | 2008-07-10 | — | — | US | disclosed |
| US-20080076917-A1 | Intermediates of 2-Substituted Carbapenem Derivatives and Process for Production Thereof | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1336612-B1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2007-01-17 | — | — | EP | disclosed |
| EP-1582522-A1 | INTERMEDIATE FOR 2-SUBSTITUTED CARBAPENEM DERIVATIVE AND PRODUCTION PROCESS | MEIJI SEIKA KAISHA LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
| US-6908913-B2 | Carbapenem derivatives | MEIJI SEIKI KAISHA, LTD. (JP) | 2005-06-21 | — | — | US | disclosed |
| US-20040038967-A1 | Novel carbapenem derivatives | MEIJI SEIKI KAISHA, LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1336612-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167475-A1 | Intermediates of 2-substituted carbapenem derivatives and process for production thereof | MGAM, G6PD, COASY | ESR1 4035/4885PTGS1 1559/4885PDE4A 1053/4885 |
| US-20080076917-A1 | Intermediates of 2-Substituted Carbapenem Derivatives and Process for Production Thereof | MGAM, G6PD, COASY | ESR1 4035/4885PTGS1 1559/4885PDE4A 1053/4885 |
| US-20040038967-A1 | Novel carbapenem derivatives | DHPS, HAMP, MCRS1 | ESR1 4851/4885PTGS1 2667/4885PDE4A 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.